Genzyme To Pay $175M Over Drug Safety Violations

Law360, New York (May 24, 2010, 4:25 PM EDT) -- Genzyme Corp. has agreed to pay $175 million to the U.S. government as part of a consent deal to remedy manufacturing violations that caused drug safety problems including viral contamination at its Allston, Mass., plant, the U.S. Food and Drug Administration said Monday.

The $175 million payment constitutes the disgorgement of profits from the sale of drugs used to treat rare genetic disorders and manufactured at the Allston facility, the FDA said.

According to the FDA, Genzyme has also agreed to hire an independent expert to...
To view the full article, register now.